Nutribiotech. Co.Ltd. said its fourth-quarter normalized net income amounted to 179.50 South Korean won per share, an increase from 78.60 won per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.56 billion won, an increase from 648.6 million won in the year-earlier period.

The normalized profit margin increased to 7.3% from 5.0% in the year-earlier period.

Total revenue grew 63.0% on an annual basis to 21.35 billion won from 13.10 billion won, and total operating expenses rose 55.9% on an annual basis to 18.69 billion won from 11.99 billion won.

Reported net income grew on an annual basis to 2.19 billion won, or 251.17 won per share, from 858.0 million won, or 103.96 won per share.

For the year, the company's normalized net income totaled 775.00 won per share, compared with the S&P Capital IQ consensus normalized EPS estimate of 395.01 won.

EPS rose from 206.91 won in the prior year.

Normalized net income was 6.47 billion won, a rise from 1.71 billion won in the prior year.

Full-year total revenue grew 65.2% from the prior-year period to 77.52 billion won from 46.91 billion won, and total operating expenses grew 53.6% on an annual basis to 66.75 billion won from 43.45 billion won.

The company said reported net income increased year over year to 8.57 billion won, or 1,025.87 won per share, in the full year, from 2.22 billion won, or 269.00 won per share.

As of March 10, US$1 was equivalent to 1,203.54 South Korean won.